ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results - Archive ouverte HAL Access content directly
Journal Articles Clinical Lymphoma, Myeloma & Leukemia Year : 2021

ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (8) , (2) , (9) , (5) , (10) , (11, 12) , (13) , (14) , (15) , (16) , (17) , (18) , (19) , (20) , (20) , (20) , (20) , (13) , (8) , (21)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Not file

Dates and versions

inserm-03546766 , version 1 (28-01-2022)

Identifiers

Cite

Jonathon Cohen, Nirav Shah, Alvaro Alencar, James Gerson, Manish Patel, et al.. ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results. Clinical Lymphoma, Myeloma & Leukemia, 2021, 21, pp.S378-S379. ⟨10.1016/S2152-2650(21)01863-2⟩. ⟨inserm-03546766⟩
8 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More